# Julian Romero

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3783021/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 84 papers | 7,588 citations | 41344 49 h-index | 62596 80 g-index |
| 85 all docs | 85 docs citations | 85 times ranked | 5306 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. Pain, 2022, 163, 834-851. | 4.2 | 17 |
| 2 | Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1. Biomedicine and Pharmacotherapy, 2022, 149, 112925. | 5.6 | 11 |
| 3 | Cannabinoid CB2 Receptors Modulate Microglia Function and Amyloid Dynamics in a Mouse Model of Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2022, 13, . | 3.5 | 10 |
| 4 | Signaling through the type 2 cannabinoid receptor regulates the severity of acute and chronic graft-versus-host disease. Blood, 2021, 137, 1241-1255. | 1.4 | 11 |
| 5 | Inactivation of the CB<sub>2</sub> receptor accelerated the neuropathological deterioration in TDPâ€43 transgenic mice, a model of amyotrophic lateral sclerosis. Brain Pathology, 2021, 31, e12972. | 4.1 | 13 |
| 6 | Potentiation of amyloid beta phagocytosis and amelioration of synaptic dysfunction upon FAAH deletion in a mouse model of Alzheimer's disease. Journal of Neuroinflammation, 2021, 18, 223. | 7.2 | 11 |
| 7 | Development of High-Specificity Fluorescent Probes to Enable Cannabinoid Type 2 Receptor Studies in Living Cells. Journal of the American Chemical Society, 2020, 142, 16953-16964. | 13.7 | 31 |
| 8 | Cannabinoid CB2R receptors are upregulated with corneal injury and regulate the course of corneal wound healing. Experimental Eye Research, 2019, 182, 74-84. | 2.6 | 22 |
| 9 | Role of interleukin 1-beta in the inflammatory response in a fatty acid amide hydrolase-knockout mouse model of Alzheimerâ€™s disease. Biochemical Pharmacology, 2018, 157, 202-209. | 4.4 | 11 |
| 10 | Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimerâ€™s disease. Journal of Neuroinflammation, 2018, 15, 158. | 7.2 | 98 |
| 11 | Revisiting cannabinoid receptor 2 expression and function in murine retina. Neuropharmacology, 2018, 141, 21-31. | 4.1 | 15 |
| 12 | Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochemical Pharmacology, 2018, 157, 67-84. | 4.4 | 75 |
| 13 | Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies. Neurobiology of Disease, 2015, 79, 41-50. | 4.4 | 34 |
| 14 | Endocannabinoids and Neurodegenerative Disorders: Parkinsonâ€™s Disease, Huntingtonâ€™s Chorea, Alzheimerâ€™s Disease, and Others. Handbook of Experimental Pharmacology, 2015, 231, 233-259. | 1.8 | 94 |
| 15 | Endocannabinoid regulation of amyloid-induced neuroinflammation. Neurobiology of Aging, 2015, 36, 3008-3019. | 3.1 | 29 |
| 16 | A restricted population of CB <sub>1</sub> cannabinoid receptors with neuroprotective activity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8257-8262. | 7.1 | 136 |
| 17 | Endocannabinoid-Hydrolysing Enzymes in the Post-Mortem Cerebellum of Humans Affected by Hereditary Autosomal Dominant Ataxias. Pathobiology, 2014, 81, 149-159. | 3.8 | 13 |
| 18 | Changes in <scp>CB<sub>1</sub></scp> and <scp>CB<sub>2</sub></scp> receptors in the postâ€mortem cerebellum of humans affected by spinocerebellar ataxias. British Journal of Pharmacology, 2014, 171, 1472-1489. | 5.4 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Mechanisms of cannabidiol neuroprotection in hypoxicâ€“ischemic newborn pigs: Role of 5HT1A and CB2 receptors. Neuropharmacology, 2013, 71, 282-291. | 4.1 | 182 |
| 20 | Î²â^'Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPARâ€Î±, PPARâ€Î³ and TRPV1, but not CB<sub>1</sub> or CB<sub>2</sub> receptors. British Journal of Pharmacology, 2012, 166, 1474-1489. | 5.4 | 65 |
| 21 | Prospects for cannabinoid therapies in basal ganglia disorders. British Journal of Pharmacology, 2011, 163, 1365-1378. | 5.4 | 98 |
| 22 | Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study. Journal of Neuroinflammation, 2011, 8, 5. | 7.2 | 92 |
| 23 | Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntingtonâ€™s disease. Brain, 2011, 134, 119-136. | 7.6 | 178 |
| 24 | The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxicâ€“ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Neurobiology of Disease, 2010, 37, 434-440. | 4.4 | 222 |
| 25 | The endocannabinoid system and amyloid-related diseases. Experimental Neurology, 2010, 224, 66-73. | 4.1 | 16 |
| 26 | The endocannabinoid system in neuropathological states. International Review of Psychiatry, 2009, 21, 172-180. | 2.8 | 30 |
| 27 | The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Research, 2009, 1283, 148-154. | 2.2 | 117 |
| 28 | Cannabinoid CB<sub>2</sub> receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease. Glia, 2009, 57, 1154-1167. | 4.9 | 165 |
| 29 | Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain, 2009, 132, 3152-3164. | 7.6 | 323 |
| 30 | Cannabinoids and Neurodegenerative Diseases. CNS and Neurological Disorders - Drug Targets, 2009, 8, 440-450. | 1.4 | 21 |
| 31 | Cannabinoid CB<sub>2</sub> receptors in human brain inflammation. British Journal of Pharmacology, 2008, 153, 277-285. | 5.4 | 244 |
| 32 | Glial expression of cannabinoid CB2 receptors and fatty acid amide hydrolase are beta amyloidâ€“linked events in Downâ€™s syndrome. Neuroscience, 2008, 151, 104-110. | 2.3 | 70 |
| 33 | Colocalization of CB1 receptors with L1 and GAP-43 in forebrain white matter regions during fetal rat brain development: Evidence for a role of these receptors in axonal growth and guidance. Neuroscience, 2008, 153, 687-699. | 2.3 | 16 |
| 34 | Cannabinoid CB<sub>1</sub> Receptors Are Expressed by Parietal Cells of the Human Gastric Mucosa. Journal of Histochemistry and Cytochemistry, 2008, 56, 511-516. | 2.5 | 22 |
| 35 | The CB2 Cannabinoid Receptor Controls Myeloid Progenitor Trafficking. Journal of Biological Chemistry, 2008, 283, 13320-13329. | 3.4 | 141 |
| 36 | Neuroprotective Effects of the Nonpsychoactive Cannabinoid Cannabidiol in Hypoxic-Ischemic Newborn Piglets. Pediatric Research, 2008, 64, 653-658. | 2.3 | 125 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Neuroinflammation and the Glial Endocannabinoid System. , 2008, , 331-359. | | 0 |
| 38 | The Cannabinoid Agonist Win55212 Reduces Brain Damage in an In Vivo Model of Hypoxic-Ischemic Encephalopathy in Newborn Rats. Pediatric Research, 2007, 62, 255-260. | 2.3 | 69 |
| 39 | Cannabinoid CB<sub>1</sub>and CB<sub>2</sub>Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis. Journal of Neuroscience, 2007, 27, 2396-2402. | 3.6 | 243 |
| 40 | The Seek of Neuroprotection: Introducing Cannabinoids. Recent Patents on CNS Drug Discovery, 2007, 2, 131-9. | 0.9 | 42 |
| 41 | Cannabinoid CB2 receptor: a new target for controlling neural cell survival?. Trends in Pharmacological Sciences, 2007, 28, 39-45. | 8.7 | 331 |
| 42 | The Endocannabinoid System and Alzheimerâ€™s Disease. Molecular Neurobiology, 2007, 36, 75-81. | 4.0 | 43 |
| 43 | Characterization of the Neuroprotective Effect of the Cannabinoid Agonist WIN-55212 in an In Vitro Model of Hypoxic-Ischemic Brain Damage in Newborn Rats. Pediatric Research, 2006, 60, 169-173. | 2.3 | 97 |
| 44 | Functional neuroanatomy of the endocannabinoid system. Pharmacology Biochemistry and Behavior, 2005, 81, 239-247. | 2.9 | 96 |
| 45 | A Glial Endogenous Cannabinoid System Is Upregulated in the Brains of Macaques with Simian Immunodeficiency Virus-Induced Encephalitis. Journal of Neuroscience, 2005, 25, 2530-2536. | 3.6 | 145 |
| 46 | Cannabinoids in neurodegeneration and neuroprotection. , 2005, , 79-109. | | 32 |
| 47 | Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver International, 2004, 24, 477-483. | 3.9 | 73 |
| 48 | Cannabinoid CB<sub>2</sub> receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study. Synapse, 2004, 53, 208-213. | 1.2 | 273 |
| 49 | Role of the endocannabinoid system in Alzheimer's disease: New perspectives. Life Sciences, 2004, 75, 1907-1915. | 4.3 | 66 |
| 50 | Effects of perinatal exposure to Î”9-tetrahydrocannabinol on operant morphine-reinforced behavior. Pharmacology Biochemistry and Behavior, 2003, 75, 577-584. | 2.9 | 38 |
| 51 | Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. Molecular Brain Research, 2003, 114, 132-139. | 2.3 | 49 |
| 52 | Cannabinoid CB<sub>2</sub>Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains. Journal of Neuroscience, 2003, 23, 11136-11141. | 3.6 | 547 |
| 53 | Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Molecular Brain Research, 2002, 100, 85-93. | 2.3 | 78 |
| 54 | The endogenous cannabinoid system and the basal ganglia. , 2002, 95, 137-152. | | 126 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Blockade of cannabinoid CB<sub>1</sub> receptor function protects against inâ€ƒvivo disseminating brain damage following NMDAâ€ƒinduced excitotoxicity. Journal of Neurochemistry, 2002, 82, 154-158. | 3.9 | 76 |
| 56 | Role of the superior colliculus in the motor effects of cannabinoids and dopamine. Brain Research, 2000, 853, 207-214. | 2.2 | 15 |
| 57 | Activational role of cannabinoids on movement. European Journal of Pharmacology, 2000, 391, 269-274. | 3.5 | 178 |
| 58 | Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sciences, 2000, 66, 485-494. | 4.3 | 100 |
| 59 | Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of Î”<sup>9</sup>â€Tetrahydrocannabinolâ€Tolerant Rats. Journal of Neurochemistry, 2000, 74, 1627-1635. | 3.9 | 144 |
| 60 | Unilateral 6-Hydroxydopamine Lesions of Nigrostriatal Dopaminergic Neurons Increased Cannabinoid CB1 Receptor mRNA Levels in the Rat Striatum: Possible Therapeutic Implications. , 2000, , 301-305. | | 0 |
| 61 | Perinatal Î” 9 -Tetrahydrocannabinol Exposure Augmented the Magnitude of Motor Inhibition Caused by GABA B , but not GABA A , Receptor Agonists in Adult Rats. Neurotoxicology and Teratology, 1999, 21, 277-283. | 2.4 | 47 |
| 62 | Pharmacological and biochemical interactions between opioids and cannabinoids. Trends in Pharmacological Sciences, 1999, 20, 287-294. | 8.7 | 364 |
| 63 | Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to Î”9-tetrahydrocannabinol. Drug and Alcohol Dependence, 1999, 55, 127-136. | 3.2 | 29 |
| 64 | Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPÎ³S binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide. Neurochemistry International, 1999, 34, 473-482. | 3.8 | 23 |
| 65 | Time-dependent differences of repeated administration with Î”9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by Î¼-opioid and CB1-cannabinoid receptors in the caudateâ€“putamen. Molecular Brain Research, 1999, 67, 148-157. | 2.3 | 61 |
| 66 | Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sciences, 1999, 65, 327-336. | 4.3 | 51 |
| 67 | Role of endocannabinoids in brain development. Life Sciences, 1999, 65, 725-736. | 4.3 | 100 |
| 68 | Identification of Endocannabinoids and Cannabinoid CB<sub>1</sub> Receptor mRNA in the Pituitary Gland. Neuroendocrinology, 1999, 70, 137-145. | 2.5 | 78 |
| 69 | Cannabinoid Receptor and WIN-55,212-2-Stimulated [<sup>35</sup>S]GTPÎ³S Binding and Cannabinoid Receptor mRNA Levels in the Basal Ganglia and the Cerebellum of Adult Male Rats Chronically Exposed to Î”<sup>9</sup>-Tetrahydrocannabinol. Journal of Molecular Neuroscience, 1998, 11, 109-120. | 2.3 | 36 |
| 70 | Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic Î³-aminobutyric acid (GABA) inputs. Biochemical Pharmacology, 1998, 56, 1331-1338. | 4.4 | 51 |
| 71 | Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to ?9-tetrahydrocannabinol. Synapse, 1998, 30, 298-308. | 1.2 | 111 |
| 72 | Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTPÎ³S binding in morphine-dependent mice. Drug and Alcohol Dependence, 1998, 50, 241-249. | 3.2 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Molecular Brain Research, 1998, 55, 126-132. | 2.3 | 82 |
| 74 | Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35s]guanylyl-5â€²-O-(thio)-triphosphate binding in the basal ganglia of aged rats. Neuroscience, 1998, 84, 1075-1083. | 2.3 | 80 |
| 75 | Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1998, 1407, 205-214. | 3.8 | 59 |
| 76 | Cannabinoid receptor binding did not vary in several hypothalamic nuclei after hypothalamic deafferentation. Life Sciences, 1998, 63, 351-356. | 4.3 | 31 |
| 77 | Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: Evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Biochemical Pharmacology, 1997, 53, 1919-1927. | 4.4 | 84 |
| 78 | THE ACTIVATION OF CANNABINOID RECEPTORS IN STRIATONIGRAL GABAERGIC NEURONS INHIBITED GABA UPTAKE. Life Sciences, 1997, 62, 351-363. | 4.3 | 83 |
| 79 | Effects of chronic exposure to Î”9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Molecular Brain Research, 1997, 46, 100-108. | 2.3 | 138 |
| 80 | Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1, receptor ligand. Life Sciences, 1996, 58, 1249-1257. | 4.3 | 57 |
| 81 | Involvement of GABAB receptors in the motor inhibition produced by agonists of brain cannabinoid receptors. Behavioural Pharmacology, 1996, 7, 299. | 1.7 | 46 |
| 82 | Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to Î´9-tetrahydrocannabinol. Pharmacology Biochemistry and Behavior, 1995, 51, 731-737. | 2.9 | 100 |
| 83 | Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Research, 1995, 694, 223-232. | 2.2 | 77 |
| 84 | The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Life Sciences, 1995, 56, 2033-2040. | 4.3 | 93 |